Candel Therapeutics, Inc.
Candel Therapeutics, Inc. (CADL) is a publicly traded company in the Unknown sector. Across all available filings, 14 corporate insiders have executed 62 transactions totaling $15.9M, demonstrating a bullish sentiment with $14.2M in net insider flow. The most recent transaction on Jul 28, 2025 involved a sale of 937 shares valued at $6.5K.
CADL Insider Activity Summary
Who Is Buying CADL Stock?
No significant insider buying has been recorded for CADL in the recent period.
Who Is Selling CADL Stock?
No significant insider selling has been recorded for CADL in the recent period.
Is Candel Therapeutics, Inc. Insider Trading Bullish or Bearish?
Based on recent SEC filings, insider sentiment for CADL is bullish with an Insider Alignment Score of 95/100 and a net flow of $14.2M. Insiders are accumulating shares, which historically signals confidence in the company's future performance.
CADL Frequently Asked Questions
Understanding CADL Insider Activity
Insider trading at Candel Therapeutics, Inc. (CADL) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 14 insiders are actively trading CADL stock, having executed 62 transactions in the past 90 days. The most active insider is Paul B. Manning (Executive), who has made 8 transactions totaling $13.4M.
Related Tools
Track Candel Therapeutics, Inc. Insider Activity
Get notified when executives and directors at CADL file new Form 4 transactions